Treatment of inoperable advanced non-small-cell lung cancer: regimens with or without taxane
Srabani Banerjee, David Moher, David J. Stewart, Canadian Coordinating Office for Health Technology Assessment
Canadian Coordinating Office for Health Technology Assessment, 2002 - Medical - 47 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Trial Quality Assessment Form
Details of Recent Studies identified after the report was written
advanced non-small cell advanced non-small-cell lung advanced NSCLC Appendix Arm Treatment Arm Belani Bonomi Bristol-Myers Squibb c=cisplatin CALGB carboplatin cb=carboplatin CCOHTA cell lung cancer chemotherapy for advanced chemotherapy regimens cisplatin Comparison of toxicity containing taxanes Cooperative Oncology Group database docetaxel dose drugs gemcitabine Eastern Cooperative Oncology etoposide Febrile neutropenia gemcitabine gemcitabine or vinorelbine Giaccone G ifosfamide inoperable advanced Jadad Leukopenia lung cancer NSCLC meta-analysis multicenter non-small cell lung non-small-cell lung cancer non-taxane arm NTRs Odds ratios paclitaxel patients with advanced performance status Pf ph phase II study phase III trial Postmus prior chemotherapy Proc Am Soc publication bias q3wk q4wk randomized phase regimens containing relevant trials response rate small cell lung Soc Clin Oncol Subgroup analyses systematic review Table taxane arm Taxol taxotere teniposide Thrombocytopenia topotecan toxicity of regimens Treatment Arm Treatment Trial abstract trial of docetaxel trial reporting TRs and NTRs versus vinorelbine vindesine vinorelbine Zandwijk